ReviewFrontiers in dementia2026
The 2024 NIA-AA biological definition of Alzheimer's disease: linking biomarkers to clinical practice.
Review in Frontiers in dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross-Sectional Study.Chemical biology & drug design · 2026Article
- Ziziphus jujuba Mill. Suspension Ameliorates Scopolamine-Induced Cognitive Impairment via PTGS2-Centered Neuroinflammatory Signaling.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria establish a biological definition of Alzheimer's disease (AD), marking a pivotal step toward linking research biomarkers with clinical practice. This review traces the evolution of AD diagnostic frameworks from the 1984 NINCDS-ADRDA clinical criteria, through biomarker-informed updates in 2011, to the 2024 biology-based criteria that bridge research and clinical care. The 2024 framework defines AD by its underlying pathology rather than clinical symptoms, recognizing that biomarker evidence alone can establish diagnosis. It expands the traditional AT (N) model into a multimodal profile (AT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.